Products

Lenalidomide (CAS 191732-72-6) is a potent immunomodulatory drug and second‑generation thalidomide analog. The molecule features an isoindolinone core with an amino group at the 4‑position and a 2,6‑dioxopiperidin‑3‑yl substituent at the 2‑position.

Pomalidomide (CAS 19171-19-8) is a potent immunomodulatory agent and third‑generation thalidomide analog. The molecule features an isoindoline‑1,3‑dione core with an amino group at the 4‑position and a 2,6‑dioxopiperidin‑3‑yl substituent at the 2‑position. This unique structural architecture enables Pomalidomide to bind cereblon (CRBN), a component of the cullin‑RING E3 ubiquitin ligase complex, with high affinity.

Erlotinib Hydrochloride (CAS 183319-69-9) is a first‑generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor belonging to the quinazolinamine class. The molecule features a quinazoline core with bis(2‑methoxyethoxy) substituents at the 6,7‑positions and an ethynylanilino group at the 4‑position, with the hydrochloride salt formed at the quinazoline nitrogen.

Sunitinib Malate (CAS 341031-54-7) is the orally bioavailable L‑malate salt of an indolinone‑based multi‑targeted receptor tyrosine kinase (RTK) inhibitor. The molecule features a pyrrole‑carboxamide core linked to an indolinone moiety via an unsaturated carbon bridge, with the L‑malate counterion enhancing the compound‘s physicochemical properties.

Trazodone Hydrochloride (CAS 25332-39-2) is a phenylpiperazine-based antidepressant belonging to the serotonin antagonist and reuptake inhibitor (SARI) class. The molecule features a triazolopyridine core linked via a propyl chain to a phenylpiperazine moiety, with the hydrochloride salt formed at the piperazine nitrogen.

Relebactam (CAS 1174018-99-5) is a novel diazabicyclooctane β‑lactamase inhibitor featuring a unique fused bicyclic core structure. The molecule comprises a 1,6-diazabicyclo[3.2.1]octane scaffold with a sulfonate group at the 6‑position and a piperidin-4-ylcarbamoyl substituent at the 2‑position.